Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma

BACKGROUND: Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis. In Europe, approved systemic therapies are limited to the PD-L1 inhibitor avelumab. For avelumab-refractory patients, efficient and safe treatment options are lacking. METHODS: A...

Descripción completa

Detalles Bibliográficos
Autores principales: Glutsch, Valerie, Kneitz, Hermann, Gesierich, Anja, Goebeler, Matthias, Haferkamp, Sebastian, Becker, Jürgen C., Ugurel, Selma, Schilling, Bastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195807/
https://www.ncbi.nlm.nih.gov/pubmed/33439294
http://dx.doi.org/10.1007/s00262-020-02832-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195807/
https://www.ncbi.nlm.nih.gov/pubmed/33439294
http://dx.doi.org/10.1007/s00262-020-02832-0

Ejemplares similares